DJO Global, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From DJO Global, Inc.
Asia Deal Watch: Hanmi Licenses Greater China Rights To Dry AMD Injectable To AffaMed
Plus deals involving GC Cell/Rivaara Immune, Sperogenix/Santhera, EOFlow/Zihipp, Grand/ITM, Tasly/Sutro, LegoChem/Iksuda, Nuance/Aerogen, Frontier/AffiRiS and Piramal/Yapan.
AAOS 2021: Digital Tools In Surgical Ecosystem, Software-Enabled Tech, Robots, Wearables, Sensors
At the live AAOS conference, exhibitors, including major orthopedics players, demoed digital innovations, software-enabled technologies, robotics and smart implants that are expected to create efficiencies in the surgical continuum and provide data to improve outcomes.
Finance Watch: Big Bucks For T-regs In Autoimmune Diseases, Inflammation
GentiBio closed a $157m series A venture capital round, while clinical trial innovator Reify Health raised a $220m series C and Neurelis secured $150m. Also, IPOs slowed in August, but Adagio and Eliem grossed $309.4m and $80m, respectively, and RNA firm Greenlight will go public in a $282m SPAC deal.
DJO Thinks Trilliant Is Brilliant, Announces Acquisition
DJO Global will buy Trilliant Surgical to further its ongoing expansion into the US foot and ankle market.
- Implantable Devices
- Rehabilitation Equipment and Devices
- Surgical Equipment & Devices
- Other Names / Subsidiaries
- Blackstone Capital Partners V L.P.
- DJO Finance LLC
- DJO Global
- Encore Medical, L.P.
- MedShape, Inc.
- Trilliant Surgical
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.